Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.
De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K. De Veirman K, et al. Among authors: de bruyne e. Cancers (Basel). 2014 Jun 27;6(3):1363-81. doi: 10.3390/cancers6031363. Cancers (Basel). 2014. PMID: 24978438 Free PMC article.
Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway.
Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I. Xu S, et al. Among authors: de becker a, de veirman k. Leukemia. 2012 Dec;26(12):2546-9. doi: 10.1038/leu.2012.126. Epub 2012 May 8. Leukemia. 2012. PMID: 22652628 No abstract available.
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.
Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I. Xu S, et al. Among authors: de becker a, de veirman k. Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8. Acta Pharmacol Sin. 2013. PMID: 23564084 Free PMC article.
Vorinostat-induced bone loss might be related to drug toxicity.
Xu S, De Veirman K, Vanderkerken K, Van Riet I. Xu S, et al. Among authors: de veirman k. Bone. 2013 Dec;57(2):384-5. doi: 10.1016/j.bone.2013.08.024. Epub 2013 Aug 30. Bone. 2013. PMID: 23999199 No abstract available.
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.
De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA. De Veirman K, et al. Among authors: de bruyne e. Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Front Oncol. 2014. PMID: 25538893 Free PMC article. Review.
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.
De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E. De Veirman K, et al. Among authors: de bruyne e, de beule n. Oncotarget. 2015 Apr 30;6(12):10532-47. doi: 10.18632/oncotarget.3300. Oncotarget. 2015. PMID: 25871384 Free PMC article.
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA, De Veirman K, Desantis V, Di Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E, Catacchio I, Ria R, Racanelli V, Maffia M, Angelucci E, Derudas D, Fumarulo R, Dammacco F, Ribatti D, Vanderkerken K, Vacca A. Frassanito MA, et al. Among authors: de veirman k. Leukemia. 2016 Mar;30(3):640-8. doi: 10.1038/leu.2015.289. Epub 2015 Oct 21. Leukemia. 2016. PMID: 26487273
54 results